Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the ...

On Wednesday, stocks declined as higher-than-expected inflation data fueled concerns that the Federal Reserve may delay rate ...

Equities in Canada’s largest centre fell short Wednesday, perhaps gun-shy after an inflation report south of the border shook up markets there. The report slashed expectations of interest rate cuts by ...

West Pharmaceutical Services Inc.’s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of injectable-pharmaceutical packaging and delivery systems offered guidance for 2025 ...

9th grade: Mckynlie Ackman, Lily Adams, Grant Alspaugh, Colton Altman, Mitchel Baker, Gordon Barks, Oren Basler, Micah Bearden, Gabrielle Bell, Liam Bergmark ...

The S&P 500 and Nasdaq showed bullish behavior, with the Dow Jones leading YTD gains at 4.7%, despite weak retail sales data.

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025 ...